Surrozen, Inc./DE

Churchill Capital Corp VII (Nasdaq: CHFW), a blank-check company sponsored by Churchill Capital Company VII LLC and part of Michael Klein's Churchill Capital franchise, completed its initial public offering in 2021 targeting the healthcare and biotechnology sector. The SPAC filed an S-1 registration statement in September 2021 in connection with its proposed business combination with Surrozen, Inc., a Delaware-incorporated clinical-stage biotechnology company focused on Wnt pathway modulation for tissue repair and regeneration. The transaction brought Surrozen to the public markets through the de-SPAC process. Sign up for full data, filings, and deal analytics on SpacDesk.